NASDAQ:WVEWave Life Sciences Stock Price, Forecast & News

Wave Life Sciences' stock was trading at $8.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, WVE stock has increased by 8.1% and is now trading at $8.78.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Wave Life Sciences.

Wave Life Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Wave Life Sciences.

Wave Life Sciences will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Wave Life Sciences Ltd (NASDAQ:WVE) announced its earnings results on Monday, May, 11th. The company reported ($1.38) EPS for the quarter, missing the Zacks' consensus estimate of ($1.34) by $0.04. The company earned $4.16 million during the quarter, compared to analyst estimates of $7.26 million. Wave Life Sciences had a negative net margin of 1,150.43% and a negative return on equity of 219.06%.
View Wave Life Sciences' earnings history.

6 brokerages have issued 1-year price targets for Wave Life Sciences' stock. Their forecasts range from $10.00 to $25.00. On average, they expect Wave Life Sciences' stock price to reach $19.20 in the next year. This suggests a possible upside of 118.7% from the stock's current price.
View analysts' price targets for Wave Life Sciences.

Media headlines about WVE stock have been trending negative recently, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Wave Life Sciences earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Wave Life Sciences.

Wave Life Sciences saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 5,010,000 shares, an increase of 6.8% from the June 15th total of 4,690,000 shares. Based on an average daily volume of 506,900 shares, the short-interest ratio is currently 9.9 days. Approximately 17.6% of the shares of the stock are short sold.
View Wave Life Sciences' Current Options Chain.

Some companies that are related to Wave Life Sciences include MacroGenics (MGNX), Passage Bio (ZNTL), Arvinas (ARVN), Theravance Biopharma (TBPH), Karyopharm Therapeutics (KPTI), Supernus Pharmaceuticals (SUPN), Odonate Therapeutics (ODT), Kiniksa Pharmaceuticals (KNSA), Constellation Pharmaceuticals (CNST), Akcea Therapeutics (AKCA), Nabriva Therapeutics (NBRV), Arcturus Therapeutics (ARCT), Esperion Therapeutics (ESPR), I-Mab (ARQT) and Akero Therapeutics (AKRO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Crispr Therapeutics (CRSP), Exelixis (EXEL), Novavax (NVAX), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Aduro BioTech (ADRO), Micron Technology (MU), AT&T (T) and TherapeuticsMD (TXMD).

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Wave Life Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Matisse Capital (0.12%), SG Americas Securities LLC (0.03%) and Assenagon Asset Management S.A. (0.03%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc.
View institutional ownership trends for Wave Life Sciences.

WVE stock was sold by a variety of institutional investors in the last quarter, including Matisse Capital. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Gregory L Verdine, Michael A Panzara, and Paul Bolno.
View insider buying and selling activity for Wave Life Sciences.

WVE stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, and Assenagon Asset Management S.A..
View insider buying and selling activity for Wave Life Sciences.

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of WVE stock can currently be purchased for approximately $8.78.

Wave Life Sciences has a market capitalization of $313.71 million and generates $15.98 million in revenue each year. The company earns $-193,640,000.00 in net income (profit) each year or ($5.72) on an earnings per share basis. Wave Life Sciences employs 250 workers across the globe.

The official website for Wave Life Sciences is www.wavelifesciences.com.

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]